US FDA’s Best Year Ever For New Drugs: CDER Novel Approvals Hit 59

FDA’s drug center smashes its past records for new molecular entities and therapeutic biologic approvals; with five novel biologics approved by FDA’s biologics center, the agency’s novel approvals reach a stunning total of 64. 

Picture showing group of friends having fun with sparklers - Image
FDA may be partially shutdown, but the agency should still celebrate its drug approval totals for 2018.

More than 90% of the US FDA’s Center for Drug Evaluation and Research actions on applications for novel agents were approvals in 2018, carrying the agency to its largest annual approval count since the modern era of the FDA was initiated by Prescription Drug User Fee Act of 1992.

CDER is known to have acted on 65 applications for new molecular entities and novel therapeutic biologics in 2018, resulting...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>